The US FDA has approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast ...

Everolimus 2mg, 3mg, 5mg; tabs for oral susp. Monitor for new or worsening respiratory symptoms; discontinue, reduce dose, and/or manage with corticosteroids if non-infectious pneumonitis occurs ...

The European Commission has approved Afinitor (everolimus), made by pharma company Novartis, for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer.

Everolimus is under clinical development by Novartis and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Most breast cancers are HER2-negative. There are many treatment options for this type of breast cancer. Your treatment will depend on factors such as hormone receptor status, cancer stage, and ...

10 ) Targeted Therapies For people with GEP-NETs that affect the pancreas, the targeted drugs everolimus (Afinitor) and sunitinib (Sutent) have been shown to slow tumor growth and improve survival.

During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, provided guidance on dosing and toxicity concerns in a patient ...

News, May 09, 2011 FDA Okays Everolimus for Rare Type of Pancreatic Cancer Everolimus (Afinitor) has been approved to treat patients with advanced pancreatic neuroendocrine tumors. News ...

According to the collective judgment of analysts, 'Revenues- Established Brands- Afinitor/Votubia - Total' should come in at $83.83 million. The estimate points to a change of -23.8% from the year ...

Evaluate the expected performance of Novartis (NVS) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics ...